Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest announcement is out from Catalyst Pharma ( (CPRX) ).
On February 26, 2026, Catalyst Pharmaceuticals reported record fourth-quarter and full-year 2025 results, with total 2025 revenues rising 19.8% year-on-year to $589.0 million and GAAP net income up 30.8% to $214.3 million. Growth was driven by FIRDAPSE, which increased 17.1% to $358.4 million, and AGAMREE, whose full-year revenue surged to $117.1 million following its March 2024 launch, while FYCOMPA revenue softened amid generic competition.
Fourth-quarter 2025 revenues reached $152.6 million, with AGAMREE up 67.5% and FIRDAPSE up 18.3% year-on-year, underscoring accelerating adoption of the company’s promoted products. Catalyst ended 2025 with $709.2 million in cash and guided 2026 total revenues to a range of $615 million to $645 million, signaling confidence in the durability of FIRDAPSE and AGAMREE, supported by favorable treatment guidelines, ongoing patent litigation management, and a strategy focused on lifecycle expansion and business development.
The most recent analyst rating on (CPRX) stock is a Buy with a $35.00 price target. To see the full list of analyst forecasts on Catalyst Pharma stock, see the CPRX Stock Forecast page.
Spark’s Take on CPRX Stock
According to Spark, TipRanks’ AI Analyst, CPRX is a Outperform.
The score is driven primarily by strong financial quality (high margins, meaningful multi-year revenue growth, and minimal leverage) and supportive earnings-call signals (record quarter and raised guidance). These positives are tempered by weak near-term technical momentum (price below key moving averages with negative MACD) and identifiable business risks noted on the call (generic pressure on FYCOMPA and ongoing patent litigation).
To see Spark’s full report on CPRX stock, click here.
More about Catalyst Pharma
Catalyst Pharmaceuticals, Inc., based in Coral Gables, Fla., is a commercial-stage biopharmaceutical company focused on rare neurological and neuromuscular diseases. Its primary promoted products include FIRDAPSE for Lambert-Eaton myasthenic syndrome, AGAMREE for Duchenne muscular dystrophy, and FYCOMPA, targeting niche patient populations in highly specialized markets.
The company’s portfolio strategy emphasizes organic growth of these branded franchises, lifecycle management to extend product value, and selective business development. Recent clinical guideline recognition for FIRDAPSE in small cell lung cancer-associated LEMS and expanding international partnerships for AGAMREE are intended to strengthen its positioning in rare disease therapeutics.
Average Trading Volume: 1,236,114
Technical Sentiment Signal: Strong Buy
Current Market Cap: $2.97B
Learn more about CPRX stock on TipRanks’ Stock Analysis page.